Liraglutide has been approved by FDA for mitigating cardiovascular disease (CVD) risks in patients with type 2 diabetes (T2D)
Minireview: update on incretin biology: focus on glucagon-like peptide-1
Maria Hanson Daniel Walker Licensed Insurance Agent Daniel Walker graduated with a BS in Administrative Management in 2005 and has run his familys insurance agency, FCI Agency, for over 15 years (BBB A+)
The most commonly reported adverse events in the Phase 2 trial were gastrointestinal in nature, including nausea, vomiting, and diarrhoea consistent with the GLP-1 receptor agonist class
This should be accounted for in research designs that include oral glucose tolerance tests or mixed meal tolerance tests, as retatrutides pharmacodynamic effects will blunt the glycemic response independent of changes in fasting glucose or insulin sensitivity
Many patients report feeling satisfied with smaller portions, which can make long-term weight management easier than relying on willpower alone
